| 1 |
Camelo S, Latil M, Agus S, Dioh W, Veillet S, Lafont R, Dilda PJ. A comparison between virus- versus patients-centred therapeutic attempts to reduce COVID-19 mortality. Emerg Microbes Infect 2021;10:2256-63. [PMID: 34783636 DOI: 10.1080/22221751.2021.2006579] [Reference Citation Analysis]
|
| 2 |
Suryantoro SD, Thaha M, Hayati MR, Yusuf M, Pikir BS, Susilo H. Correlation between anti-hypertensive drugs and disease progression among moderate, severe, and critically ill COVID-19 patients in the second referral hospital in Surabaya: A retrospective cohort study. F1000Res 2021;10:393. [PMID: 34912542 DOI: 10.12688/f1000research.51785.2] [Reference Citation Analysis]
|
| 3 |
Barh D, Aljabali AA, Tambuwala MM, Tiwari S, Serrano-Aroca Á, Alzahrani KJ, Silva Andrade B, Azevedo V, Ganguly NK, Lundstrom K. Predicting COVID-19-Comorbidity Pathway Crosstalk-Based Targets and Drugs: Towards Personalized COVID-19 Management. Biomedicines 2021;9:556. [PMID: 34067609 DOI: 10.3390/biomedicines9050556] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 4 |
Soldevila L, Valerio-Sallent L, Roure S, Pérez-Quílez O, Mas MÀ, Miralles R, López-Muñoz I, Estrada O, Vallès X. Drug exposure may have a substantial influence on COVID-19 prognosis among residents of long-term care facilities: an exploratory analysis. Int J Infect Dis 2021;109:192-4. [PMID: 34242767 DOI: 10.1016/j.ijid.2021.07.007] [Reference Citation Analysis]
|
| 5 |
Acanfora D, Acanfora C, Ciccone MM, Scicchitano P, Bortone AS, Uguccioni M, Casucci G. The Cross-Talk between Thrombosis and Inflammatory Storm in Acute and Long-COVID-19: Therapeutic Targets and Clinical Cases. Viruses 2021;13:1904. [PMID: 34696334 DOI: 10.3390/v13101904] [Reference Citation Analysis]
|
| 6 |
Martínez-urbistondo M, Moreno-torres V, Mora-vargas A, Expósito-palomo E, Castejón-díaz R, Daimiel L, Ramos-lopez O, San-cristóbal R, Vargas JA, Martínez JA. Interaction of ACEI antihypertensive agent's administration with the inflammatory status at admission concerning COVID-19 clinical stay outcomes. Vascular Pharmacology 2022. [DOI: 10.1016/j.vph.2022.106955] [Reference Citation Analysis]
|
